EUVIMEDEUVIMED entdecken
Open Access

Refining antifibrotic therapy in idiopathic pulmonary fibrosis: can deuteration improve on pirfenidone?

Chad A Newton iD

American Journal of Respiratory and Critical Care Medicine · 01.08.2026 · 212 (8) · 1686-1687

DOI: 10.1093/ajrccm/aamag237 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Respiratory and Critical Care Medicine, online erschienen am 18.05.2026. Verfasst von Chad A Newton. Beteiligte Einrichtung: Division of Pulmonary and Critical Care Medicine, University of Texas Southwestern Medical Center, Dallas, TX, United States. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Division of Pulmonary and Critical Care Medicine, University of Texas Southwestern Medical Center, Dallas, TX, United States.

ORCID-Profile: Chad A Newton

Förderung

  • NHLBI NIH HHS
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Newton, C. A. (2026). Refining antifibrotic therapy in idiopathic pulmonary fibrosis: can deuteration improve on pirfenidone?. American Journal of Respiratory and Critical Care Medicine, 212(8), 1686-1687. https://doi.org/10.1093/ajrccm/aamag237

Vancouver

Newton CA. Refining antifibrotic therapy in idiopathic pulmonary fibrosis: can deuteration improve on pirfenidone?. American Journal of Respiratory and Critical Care Medicine. 2026;212(8):1686-1687. doi:10.1093/ajrccm/aamag237

BibTeX
@article{Newton2026,
  author = {Newton, Chad A},
  title = {Refining antifibrotic therapy in idiopathic pulmonary fibrosis: can deuteration improve on pirfenidone?},
  journal = {American Journal of Respiratory and Critical Care Medicine},
  year = {2026},
  volume = {212},
  number = {8},
  pages = {1686--1687},
  doi = {10.1093/ajrccm/aamag237}
}
Kostenlos starten →